{"id":"an2690-2-5","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting KCNN4, AN2690 is thought to reduce the excitability of neurons and potentially alleviate symptoms of certain neurological disorders. The exact mechanism of action is still being investigated, but it is believed to involve a reduction in the release of neurotransmitters and a decrease in neuronal excitability.","oneSentence":"AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:09:14.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of essential tremor"}]},"trialDetails":[{"nctId":"NCT00680095","phase":"PHASE1","title":"Cumulative Irritation Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-01-22","conditions":"Onychomycosis","enrollment":37},{"nctId":"NCT00679965","phase":"PHASE2","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02-28","conditions":"Distal, Subungual Onychomycosis","enrollment":159},{"nctId":"NCT00679770","phase":"PHASE2","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-06-30","conditions":"Distal, Subungual Onychomycosis","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AN2690, 2.5%","genericName":"AN2690, 2.5%","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AN2690 is a treatment being studied for onychomycosis, specifically distal, subungual onychomycosis, and onychomycosis, in clinical trials. The treatment is being tested in different concentrations, including 2.5%, 5%, and 7.5%, in a randomized, double-blind, vehicle-controlled study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}